 This trial will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of repeat dosing of UTTR1147A in participants with neuropathic diabetic foot ulcers that do not respond adequately to standard wound care. Participants across multiple sites will be assigned to one of four cohorts Cohort A, B, C, and D based on the eligibility criteria and randomized to receive subcutaneous SC injections of either UTTR1147A or placebo over 12 weeks in addition to standard wound care. 